Floatz logo

Modotuximab

Squamous Non-Small Cell Lung Cancer

Symphogen A/Smonoclonal_antibodyPhase 1/2Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Squamous Non-Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Atezolizumab
Imugene Limited
Phase 3BB
rac-(2R)-(9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid
Ability Pharmaceuticals SL
Phase 1/2CCC
Avelumab
Merck KGaA, Darmstadt, Germany
Phase 2CCC
Rilvegostomig
AstraZeneca
Phase 1/2CCC
Lumretuzumab
Hoffmann-La Roche
Phase 1/2CCC
Puxitatug Samrotecan
AstraZeneca
Phase 1/2CCC
Lucitanib
Clovis Oncology, Inc.
Phase 2CC

Same molecule, other indications

Modotuximab is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
47 / 100
View asset →
Colorectal Cancer MetastaticDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →